gemcitabine has been researched along with gastrins in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clarke, PA; Evans, SA; Gilliam, AD; Grabowska, AM; Harris, JC; McKenzie, AJ; McWilliams, DF; Watson, SA | 1 |
| Von Hoff, DD | 1 |
| Emori, Y; Eta, R; Hamano, H; Iino, Y; Kawasaki, D; Takei, M; Tanaka, T; Watson, SA; Yoshinaga, K | 1 |
| Borbath, I; Caplin, ME; Coxon, F; Kato, H; Larvin, M; Meyer, T; Nagano, E; Palmer, DH; Peeters, M; Valle, JW; Waters, JS | 1 |
| Hori, Y; Kuki, K; Shiomi, Y; Tanaka, T; Yoshimura, M | 1 |
1 review(s) available for gemcitabine and gastrins
| Article | Year |
|---|---|
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
1 trial(s) available for gemcitabine and gastrins
| Article | Year |
|---|---|
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Female; Gastrins; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Receptor, Cholecystokinin B; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2010 |
3 other study(ies) available for gemcitabine and gastrins
| Article | Year |
|---|---|
The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA, Antisense; Docetaxel; Gastrins; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Precursors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Taxoids; Transfection | 2004 |
Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Gastrins; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Cholecystokinin B; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice
Topics: Animals; Apoptosis; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endopeptidases; Gastrins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survivin; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2017 |